Avid Bioservices (CDMO) reported a fiscal Q1 net loss Monday of $0.09 per diluted share, wider than a loss of $0.03 a year earlier.
Four analysts polled by Capital IQ expected a per-share loss of $0.06.
Revenue for the quarter ended July 31 was $40.2 million, up from $37.7 million a year earlier.
Analysts surveyed by Capital IQ expected $40.8 million.
The company reiterated its revenue guidance for fiscal 2025 of between $160 million and $168 million.
Analysts polled by Capital IQ expect $162.8 million.
Price: 8.90, Change: -0.05, Percent Change: -0.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.